<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30184615</PMID>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>05</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">2005-6648</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Sep</Month>                        <Day>06</Day>                    </PubDate>                </JournalIssue>                <Title>The Korean journal of internal medicine</Title>                <ISOAbbreviation>Korean J. Intern. Med.</ISOAbbreviation>            </Journal>            <ArticleTitle>Prognostic role of beclin-1 in locally advanced non-small cell lung cancer in patients receiving docetaxel-platinum induction chemotherapy.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.3904/kjim.2017.015</ELocationID>            <Abstract>                <AbstractText Label="Background/Aims" NlmCategory="UNASSIGNED">The outcome of local treatment for advanced non-small cell lung cancer (NSCLC) remains poor, with therapies such as induction chemotherapy (IC) yielding conflicting results. This study aimed to assess the clinicopathologic and prognostic significance of the excision repair cross-complementation group 1 (ERCC1), beclin-1, and glucose-regulated protein of molecular mass 78 (GRP78) in patients with locally advanced NSCLC receiving docetaxel-platinum IC, along with efficacy and safety.</AbstractText>                <AbstractText Label="Methods" NlmCategory="UNASSIGNED">This is a retrospective observational cohort study. We reviewed medical records of 31 NSCLC patients receiving docetaxel-platinum IC, and conducted immunohistochemical staining of ERCC1, beclin-1, and GRP78.</AbstractText>                <AbstractText Label="Results" NlmCategory="UNASSIGNED">Response rate was 67.8% with 10.7 months of median relapse-free survival (RFS) and 23.1 months of median overall survival (OS), and no treatment-related death was reported. High expression of ERCC1, beclin-1, and GRP78 was identified in 67.7%, 87.1%, and 67.7%, respectively. Expression of ERCC1 and GRP78 did not reveal statistical significance in survival, whereas high beclin-1 expression revealed longer OS (7.6 months vs. 23.2 months; log-rank p = 0.024). In multivariate analysis, histologic differentiation (hazard ratio [HR], 3.48; p &lt; 0.001), stage (HR, 8.5; p = 0.024), and adjuvant treatment (HR, 16.1; p = 0.001) were related to RFS, and in OS, stage (HR, 5.4; p = 0.037), adjuvant treatment (HR, 8.6; p = 0.004), and beclin-1 expression (HR, 8.2; p = 0.011) were identified as significant prognostic factors.</AbstractText>                <AbstractText Label="Conclusions" NlmCategory="UNASSIGNED">Our findings suggest that high beclin-1 expression predicts longer survival in locally advanced NSCLC and docetaxel-platinum IC is a treatment option that deserves consideration.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Lee</LastName>                    <ForeName>Hee Yeon</ForeName>                    <Initials>HY</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Internal Medicine, College of Medicine, Incheon St. Mary's Hospital, The Catholic University of Korea, Incheonm, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Shin</LastName>                    <ForeName>Jung Ha</ForeName>                    <Initials>JH</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pathology, College of Medicine, St. Paul's Hospital, The Catholic University of Korea, Seoul, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lee</LastName>                    <ForeName>Kyo-Young</ForeName>                    <Initials>KY</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pathology, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Park</LastName>                    <ForeName>Jae Kil</ForeName>                    <Initials>JK</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Thoracic and Cardiovascular Surgery, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sung</LastName>                    <ForeName>Sook Whan</ForeName>                    <Initials>SW</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Thoracic and Cardiovascular Surgery, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kim</LastName>                    <ForeName>Yeon Sil</ForeName>                    <Initials>YS</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Radiation Oncology, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kang</LastName>                    <ForeName>Jin-Hyoung</ForeName>                    <Initials>JH</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Internal Medicine, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kim</LastName>                    <ForeName>Jeong-Oh</ForeName>                    <Initials>JO</Initials>                    <AffiliationInfo>                        <Affiliation>Laboratory of Medical Oncology, Cancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Korea.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>06</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Korea (South)</Country>            <MedlineTA>Korean J Intern Med</MedlineTA>            <NlmUniqueID>8712418</NlmUniqueID>            <ISSNLinking>1226-3303</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">BECN1 protein, human</Keyword>            <Keyword MajorTopicYN="N">Carcinoma, non-small-cell lung</Keyword>            <Keyword MajorTopicYN="N">Induction chemotherapy</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2017</Year>                <Month>01</Month>                <Day>06</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2017</Year>                <Month>07</Month>                <Day>19</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30184615</ArticleId>            <ArticleId IdType="pii">kjim.2017.015</ArticleId>            <ArticleId IdType="doi">10.3904/kjim.2017.015</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30184548</PMID>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>05</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1421-9778</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>49</Volume>                    <Issue>3</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Sep</Month>                        <Day>05</Day>                    </PubDate>                </JournalIssue>                <Title>Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology</Title>                <ISOAbbreviation>Cell. Physiol. Biochem.</ISOAbbreviation>            </Journal>            <ArticleTitle>Exosomal miR-27a Derived from Gastric Cancer Cells Regulates the Transformation of Fibroblasts into Cancer-Associated Fibroblasts.</ArticleTitle>            <Pagination>                <MedlinePgn>I</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1159/000493218</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND/AIMS" NlmCategory="OBJECTIVE">The malignant biological behavior of gastric cancer(GC) is not only determined by cancer cells alone, but also closely regulated by the microenvironment. Fibroblasts represent a large proportion of the components in the tumor microenvironment, and they promote the development of disease. Currently, accumulating evidence suggests that exosomes can function as intercellular transport systems to relay their contents, especially microRNAs(miRNAs).</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">First, we detected the highly-expressed level of miR-27a in exosomes isolated from gastric cancer cells by qRT-PCR. MiR-27a -over-expressed models in vitro and in vivo were established to investigate the transformation of cancer-associated fibroblasts observed by Western blotting, and the malignant behavior of gastric cancer cells using the methods CCK8 and Transwell. Moreover, the downregulation of CSRP2 in fibroblasts was used to evaluate the promotion of malignancy of gastric cancer using the methods CCK8 and Transwell.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">In this study, we found a marked high level of miR-27a in exosomes derived from GC cells. miR-27a was found to function an oncogene that not only induced the reprogramming of fibroblasts into cancer-associated fibroblasts(CAFs), but also promoted the proliferation, motility and metastasis of cancer cells in vitro and in vivo. Conversely, CAFs with over-expression of miR-27a could pleiotropically increase the malignant behavior of the GC cells. For the first time, we revealed that CSRP2 is a downstream target of miR-27a. CSRP2 downregulation could increase the proliferation and motility of GC cells.</AbstractText>                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Thus, this report indicates that miR-27a in exosomes derived from GC cells has a crucial impact on the microenvironment and may be used as a potential therapeutic target in the treatment of GC.</AbstractText>                <CopyrightInformation>© 2018 The Author(s). Published by S. Karger AG, Basel.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Wang</LastName>                    <ForeName>Jingya</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Thoracic Oncology, Tianjin Lung Cancer Center,, Tianjin, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Guan</LastName>                    <ForeName>Xuwen</ForeName>                    <Initials>X</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Thoracic Oncology, Tianjin Lung Cancer Center,, Tianjin, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhang</LastName>                    <ForeName>Yue</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Thoracic Oncology, Tianjin Lung Cancer Center,, Tianjin, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ge</LastName>                    <ForeName>Shaohua</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Gastrointestinal Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhang</LastName>                    <ForeName>Le</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Gastrointestinal Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Li</LastName>                    <ForeName>Hongli</ForeName>                    <Initials>H</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Gastrointestinal Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wang</LastName>                    <ForeName>Xia</ForeName>                    <Initials>X</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Gastrointestinal Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Liu</LastName>                    <ForeName>Rui</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Gastrointestinal Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ning</LastName>                    <ForeName>Tao</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Gastrointestinal Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Deng</LastName>                    <ForeName>Ting</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Gastrointestinal Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhang</LastName>                    <ForeName>Haiyang</ForeName>                    <Initials>H</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Gastrointestinal Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Jiang</LastName>                    <ForeName>Xiangli</ForeName>                    <Initials>X</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Thoracic Oncology, Tianjin Lung Cancer Center,, Tianjin, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ba</LastName>                    <ForeName>Yi</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Gastrointestinal Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Huang</LastName>                    <ForeName>Dingzhi</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Thoracic Oncology, Tianjin Lung Cancer Center,, Tianjin, China.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>05</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Switzerland</Country>            <MedlineTA>Cell Physiol Biochem</MedlineTA>            <NlmUniqueID>9113221</NlmUniqueID>            <ISSNLinking>1015-8987</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">CSRP2</Keyword>            <Keyword MajorTopicYN="N">Cancer associated fibroblasts</Keyword>            <Keyword MajorTopicYN="N">Exosome</Keyword>            <Keyword MajorTopicYN="N">Gastric cancer</Keyword>            <Keyword MajorTopicYN="N">Tumor microenvironment</Keyword>            <Keyword MajorTopicYN="N">miR-27a</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>02</Month>                <Day>28</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>08</Month>                <Day>27</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30184548</ArticleId>            <ArticleId IdType="pii">000493218</ArticleId>            <ArticleId IdType="doi">10.1159/000493218</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="In-Data-Review" Owner="NLM">        <PMID Version="1">30183753</PMID>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>05</Day>        </DateRevised>        <Article PubModel="Electronic-eCollection">            <Journal>                <ISSN IssnType="Electronic">1932-6203</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>13</Volume>                    <Issue>9</Issue>                    <PubDate>                        <Year>2018</Year>                    </PubDate>                </JournalIssue>                <Title>PloS one</Title>                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>            </Journal>            <ArticleTitle>Dosimetric superiority of IMRT with jaw tracking technique for whole esophagus and T-shaped field radiotherapy in advanced esophageal cancer.</ArticleTitle>            <Pagination>                <MedlinePgn>e0202628</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0202628</ELocationID>            <Abstract>                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">For whole esophagus and T-shaped field radiotherapy using intensity modulated radiotherapy (IMRT) technique in advanced esophageal cancer, lower absorbed doses to lung and heart remains a challenge. The aim of this study was to investigate the dosimetric superiority in IMRT plans with jaw tracking technique for whole esophagus radiotherapy.</AbstractText>                <AbstractText Label="METHODS AND MATERIALS" NlmCategory="METHODS">Thirty-two patients with esophageal cancer were subjected to IMRT treatment plans using Eclipse treatment planning system. For every patient, four different plans were generated with six gantry angles: six large fields IMRT plans with fixed jaw (6F-IMRT), six large fields IMRT plans with jaw tracking technique (6F-IMRT-T), twelve small fields IMRT plans with fixed jaw (12F-IMRT), and twelve small fields IMRT plans with jaw tracking technique (12F-IMRT-T). Dosimetric evaluation was assessed for all plans.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">For every technique, there were no differences in planning target volume (PTV) coverage and conformity. 6F-IMRT-T plans could significantly reduce lung irradiation with 7.9% (P&lt;0.001) reduction in V5lung and 2.5% (P&lt;0.001) reduction in V20 lung respectively compared to 6F-IMRT plans. 12F-IMRT-T plans resulted in superior plans compared to 12-IMRT plans with a reduction of 2.9% (P&lt;0.001) in V5lung and 0.9% (P&lt;0.001) in V20 lung, respectively. For heart irradiation, 6F-IMRT-T and 12F-IMRT-T plans were slightly superior to 6F-IMRT and 12-IMRT plans respectively with a reduction of 1.1 Gy and 0.5 Gy in the respective mean doses.</AbstractText>                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">By the use of jaw tracking technique, the IMRT plans resulted in further lung and heart sparing compared to fixed jaw plans for radiotherapy in esophageal cancer.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Shi</LastName>                    <ForeName>Liwan</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Radiation Oncology, Xiamen Cancer Hospital, The First Affiliated Hospital of Xiamen University, Xiamen, PR China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lai</LastName>                    <ForeName>Youqun</ForeName>                    <Initials>Y</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0001-5417-8312</Identifier>                    <AffiliationInfo>                        <Affiliation>Department of Radiation Oncology, Xiamen Cancer Hospital, The First Affiliated Hospital of Xiamen University, Xiamen, PR China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Chen</LastName>                    <ForeName>Shanyu</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Radiation Oncology, Xiamen Cancer Hospital, The First Affiliated Hospital of Xiamen University, Xiamen, PR China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Fu</LastName>                    <ForeName>Lirong</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Radiation Oncology, Xiamen Cancer Hospital, The First Affiliated Hospital of Xiamen University, Xiamen, PR China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lin</LastName>                    <ForeName>Qin</ForeName>                    <Initials>Q</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Radiation Oncology, Xiamen Cancer Hospital, The First Affiliated Hospital of Xiamen University, Xiamen, PR China.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>05</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>PLoS One</MedlineTA>            <NlmUniqueID>101285081</NlmUniqueID>            <ISSNLinking>1932-6203</ISSNLinking>        </MedlineJournalInfo>        <CoiStatement>The authors have declared that no competing interests exist.</CoiStatement>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2017</Year>                <Month>06</Month>                <Day>08</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>08</Month>                <Day>07</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30183753</ArticleId>            <ArticleId IdType="doi">10.1371/journal.pone.0202628</ArticleId>            <ArticleId IdType="pii">PONE-D-17-20664</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30183684</PMID>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>05</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1361-6560</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Sep</Month>                        <Day>05</Day>                    </PubDate>                </JournalIssue>                <Title>Physics in medicine and biology</Title>                <ISOAbbreviation>Phys Med Biol</ISOAbbreviation>            </Journal>            <ArticleTitle>Method for optimizing planning target volume margin for patients receiving lung stereotactic body radiotherapy.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1088/1361-6560/aadf26</ELocationID>            <Abstract>                <AbstractText>Lung stereotactic-body radiotherapy (SBRT) places additional requirements on targeting accuracy over standard approaches. In treatment planning, a tumour volume is geometrically expanded and the resulting planning target volume (PTV) is covered with full dose. This ensures full dose delivery despite various uncertainties encountered during treatment. &amp;#13; &amp;#13; We developed a retrospective technique for optimizing the PTV expansion for a patient population. The method relies on deformable image registration (DIR) of the planning CT to a treatment cone-beam CT (CBCT). The resulting transformation is used to map the planned target onto the treatment geometry, allowing the computation of the achieved target/PTV overlap. &amp;#13; &amp;#13; Basic validation of the method was performed using an anthropomorphic respiratory motion phantom. A self-validation technique was also implemented to allow estimation of the DIR error for the data being analyzed. Our workflow was used to retrospectively optimize PTV margin for 25 patients treated over 93 fractions. Targets for these patients were contoured on four-dimensional CT images. SBRT delivery followed CBCT acquisition and a couch correction. A post-treatment CBCT was also acquired in some cases. &amp;#13; &amp;#13; Our basic validation demonstrated that the DIR-based technique is capable of transforming targets volumes from planning CTs to treatment CBCTs with sub-mm accuracy. Our clinical analysis showed that the minimum percentages of target volumes covered for 3, 4, and 5mm PTV margins were 92.1, 97.6, and 99.2, respectively. Analyzing data acquired before and just after treatment demonstrated that margins exceeding 5mm did not significantly improve coverage. Finally, a 5mm PTV margin achieved ≥95% target volume coverage with ≥95% probability.&amp;#13; &amp;#13; Our technique is accurate, automated, self-validating, and incorporates complex ITV shapes/deformations to allow PTV margin optimization. The analysis of clinical data indicates a 5mm PTV margin is optimal for our process. This approach is generalizable to other disease sites and treatment strategies. &amp;#13.</AbstractText>                <CopyrightInformation>© 2018 Institute of Physics and Engineering in Medicine.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Wierzbicki</LastName>                    <ForeName>Marcin</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Medical Physics, Juravinski Cancer Centre, 699 Concession St, Hamilton, Ontario, L8V 5C2, CANADA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Mathew</LastName>                    <ForeName>Lindsay</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Medical Physics, Abbotsford Regional Hospital and Cancer Centre, Abbotsford, British Columbia, CANADA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Swaminath</LastName>                    <ForeName>Anand</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Radiation Oncology, Juravinski Cancer Centre, Hamilton, Ontario, CANADA.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>05</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>Phys Med Biol</MedlineTA>            <NlmUniqueID>0401220</NlmUniqueID>            <ISSNLinking>0031-9155</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">deformable registration</Keyword>            <Keyword MajorTopicYN="N">image guided radiotherapy</Keyword>            <Keyword MajorTopicYN="N">lung stereotactic body radiotherapy</Keyword>            <Keyword MajorTopicYN="N">planning target volume margin</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30183684</ArticleId>            <ArticleId IdType="doi">10.1088/1361-6560/aadf26</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30183677</PMID>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>05</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1361-6560</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Sep</Month>                        <Day>05</Day>                    </PubDate>                </JournalIssue>                <Title>Physics in medicine and biology</Title>                <ISOAbbreviation>Phys Med Biol</ISOAbbreviation>            </Journal>            <ArticleTitle>An augmented correlation framework for the estimation of tumour translational and rotational motion during external beam radiotherapy treatments using intermittent monoscopic X-ray imaging and an external respiratory signal.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1088/1361-6560/aadf2c</ELocationID>            <Abstract>                <AbstractText>Increasing evidence shows that intrafraction tumour motion monitoring must include both six degrees of freedom (6DoF): 3D translations and 3D rotations. Existing real- time algorithms for 6DoF target motion estimation requires continuous intrafraction fluoroscopic imaging at high frequency, thereby exposing patients to additional high imaging dose. This paper presents the first method capable of 6DoF motion monitoring using intermittent 2D kV imaging and a continuous external respiratory signal.&amp;#13; Method: Our approach is to optimise a state-augmented linear correlation model between an external signal and internal 6DoF motion. In standard treatments, the model can be built using information obtained during pre-treatment CBCT. Real-time 6DoF tumor motion can then be estimated using just the external signal. Intermittent intrafraction kV images are used to update the model parameters, accounting for changes in correlation and baseline shifts.&amp;#13; The method was evaluated in silico using data from 6 lung SABR patients, with the internal tumour motion recorded with electromagnetic beacons and the external signal from a bellows belt. Projection images from CBCT (10 Hz) and intermittent kV images were simulated by projecting the 3D Calypso beacon positions onto an imager. IMRT and VMAT treatments were simulated with increasing imaging update intervals: 0.1 s, 1 s, 3 s, 10 s and 30 s.&amp;#13; Results: For all the tested clinical scenarios, translational motion estimates with our method had sub-mm accuracy (mean) and precision (standard deviation) while rotational motion estimates were accurate to &amp;lt;1° and precise to 2°. Motion estimation errors increased as the imaging update interval increased. With the largest imaging update interval (30 s), the errors were 0.1±0.6 mm, -0.0±0.7 mm and 0.1±0:9 mm for translation in the Left-Right, Superior-Inferior and Anterior-Posterior directions, respectively, and 0.1±1.3°, -0.3±2.0° and 0.1±0:9° for rotation around the aforementioned axes for both VMAT and IMRT treatments.</AbstractText>                <CopyrightInformation>© 2018 Institute of Physics and Engineering in Medicine.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Nguyen</LastName>                    <ForeName>Doan Trang</ForeName>                    <Initials>DT</Initials>                    <Identifier Source="ORCID">0000-0003-1581-0359</Identifier>                    <AffiliationInfo>                        <Affiliation>Radiation Physics Laboratory - School of Medicine, University of Sydney, Blackburn building, The University of Sydney, Sydney, New South Wales, 2006, AUSTRALIA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Booth</LastName>                    <ForeName>Jeremy Todd</ForeName>                    <Initials>JT</Initials>                    <AffiliationInfo>                        <Affiliation>Radiation Oncology, Northern Sydney Cancer Centre, Level 1 Royal North Shore Hospital, St Leonards, New South Wales, 2065, AUSTRALIA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Caillet</LastName>                    <ForeName>Vincent</ForeName>                    <Initials>V</Initials>                    <AffiliationInfo>                        <Affiliation>Faculty of Medicine, University of Sydney, Sydney, New South Wales, AUSTRALIA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hardcastle</LastName>                    <ForeName>Nicholas</ForeName>                    <Initials>N</Initials>                    <AffiliationInfo>                        <Affiliation>Radiation Oncology, Peter MacCallum Cancer Institute, Melbourne, Victoria, AUSTRALIA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Briggs</LastName>                    <ForeName>Adam</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Royal North Shore Hospital Northern Sydney Cancer Centre, Saint Leonards, New South Wales, AUSTRALIA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Haddad</LastName>                    <ForeName>Carol</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Radiation Oncology, Northern Sydney Cancer Centre, St Leonards, New South Wales, AUSTRALIA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Eade</LastName>                    <ForeName>Thomas</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>Royal North Shore Hospital Northern Sydney Cancer Centre, Saint Leonards, New South Wales, AUSTRALIA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>O'Brien</LastName>                    <ForeName>Ricky T</ForeName>                    <Initials>RT</Initials>                    <AffiliationInfo>                        <Affiliation>Radiation Physics Laboratory, Sydney Medical School, University of Sydney, NSW 2006, Camperdown, New South Wales, 2039, AUSTRALIA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Keall</LastName>                    <ForeName>Paul J</ForeName>                    <Initials>PJ</Initials>                    <AffiliationInfo>                        <Affiliation>Sydney Medical School - Central, University of Sydney, Edward Ford Building A27, The University of Sydney, NSW 2006, Sydney, AUSTRALIA.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>05</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>Phys Med Biol</MedlineTA>            <NlmUniqueID>0401220</NlmUniqueID>            <ISSNLinking>0031-9155</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">internal-external correlation</Keyword>            <Keyword MajorTopicYN="N">intrafraction motion</Keyword>            <Keyword MajorTopicYN="N">lung cancer</Keyword>            <Keyword MajorTopicYN="N">real-time monitoring</Keyword>            <Keyword MajorTopicYN="N">six degrees of freedom motion</Keyword>            <Keyword MajorTopicYN="N">tumour rotation</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30183677</ArticleId>            <ArticleId IdType="doi">10.1088/1361-6560/aadf2c</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30183476</PMID>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>05</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1555-8576</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Sep</Month>                        <Day>05</Day>                    </PubDate>                </JournalIssue>                <Title>Cancer biology &amp; therapy</Title>                <ISOAbbreviation>Cancer Biol. Ther.</ISOAbbreviation>            </Journal>            <ArticleTitle>Sodium chloride (NaCl) potentiates digoxin-induced anti-tumor activity in small cell lung cancer.</ArticleTitle>            <Pagination>                <MedlinePgn>1-13</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1080/15384047.2018.1504723</ELocationID>            <Abstract>                <AbstractText>Small cell lung cancer (SCLC) is a malignant neuroendocrine tumor with very high mortality. Effective new therapy for advanced SCLC patients is urgently needed. By screening a FDA-approved drug library, we identified a cardiac glycoside (CG), namely digoxin (an inhibitor of cellular Na<sup>+</sup>/K<sup>+</sup> ATPase pump), which was highly effective in inhibiting SCLC cell growth. Intriguing findings showed that NaCl supplement markedly enhanced the anti-tumor activities of digoxin in both in vitro and in vivo models of SCLC. Subsequent analysis revealed that this novel combination of digoxin/NaCl caused an up-regulation of intracellular Na<sup>+</sup> and Ca<sup>2+</sup> levels with an induction of higher resting membrane potential of SCLC cells. We also found that this combination lead to morphological shrinking of SCLC cells, together with high levels of cytochrome C release. Lastly, our data revealed that NaCl supplement was able to induce the expression of ATP1A1 (a Na<sup>+</sup>/K<sup>+</sup> ATPase subunit), in which contributes directly to the increased sensitivity of SCLC cells to digoxin. Thus, this is the first demonstration that NaCl is a potent supplement necessitating superior anti-cancer effects of digoxin for SCLC. Further, our study suggests that digoxin treatment could need to be combined with NaCl supplement in future clinical trial of SCLC, particularly where low Na<sup>+</sup> is often present in SCLC patients.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Deng</LastName>                    <ForeName>Ke</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>a High Magnetic Field Laboratory , Chinese Academy of Sciences , Hefei , P. R. China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>b University of Science and Technology of China , Hefei , P. R. China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>c Key Laboratory of High Magnetic Field and Ion Beam Physical Biology, Hefei Institutes of Physical Science , Chinese Academy of Sciences , Hefei , P. R. China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Shen</LastName>                    <ForeName>Jiawei</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>d School of Life Sciences , University of Science and Technology of China , Hefei , P. R. China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wang</LastName>                    <ForeName>Wei</ForeName>                    <Initials>W</Initials>                    <AffiliationInfo>                        <Affiliation>a High Magnetic Field Laboratory , Chinese Academy of Sciences , Hefei , P. R. China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>c Key Laboratory of High Magnetic Field and Ion Beam Physical Biology, Hefei Institutes of Physical Science , Chinese Academy of Sciences , Hefei , P. R. China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Li</LastName>                    <ForeName>Ming</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>a High Magnetic Field Laboratory , Chinese Academy of Sciences , Hefei , P. R. China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>b University of Science and Technology of China , Hefei , P. R. China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>c Key Laboratory of High Magnetic Field and Ion Beam Physical Biology, Hefei Institutes of Physical Science , Chinese Academy of Sciences , Hefei , P. R. China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>e Department of Laboratory Diagnostics , Western Branch of The First Affiliated Hospital of University of Science and Technology of China , Hefei , P. R. China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Li</LastName>                    <ForeName>Hong</ForeName>                    <Initials>H</Initials>                    <AffiliationInfo>                        <Affiliation>a High Magnetic Field Laboratory , Chinese Academy of Sciences , Hefei , P. R. China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>c Key Laboratory of High Magnetic Field and Ion Beam Physical Biology, Hefei Institutes of Physical Science , Chinese Academy of Sciences , Hefei , P. R. China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Chen</LastName>                    <ForeName>Cheng</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>a High Magnetic Field Laboratory , Chinese Academy of Sciences , Hefei , P. R. China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>b University of Science and Technology of China , Hefei , P. R. China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>c Key Laboratory of High Magnetic Field and Ion Beam Physical Biology, Hefei Institutes of Physical Science , Chinese Academy of Sciences , Hefei , P. R. China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhao</LastName>                    <ForeName>Huan</ForeName>                    <Initials>H</Initials>                    <AffiliationInfo>                        <Affiliation>d School of Life Sciences , University of Science and Technology of China , Hefei , P. R. China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhang</LastName>                    <ForeName>Mei</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>d School of Life Sciences , University of Science and Technology of China , Hefei , P. R. China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Xue</LastName>                    <ForeName>Tian</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>d School of Life Sciences , University of Science and Technology of China , Hefei , P. R. China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Liu</LastName>                    <ForeName>Qingsong</ForeName>                    <Initials>Q</Initials>                    <AffiliationInfo>                        <Affiliation>a High Magnetic Field Laboratory , Chinese Academy of Sciences , Hefei , P. R. China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>c Key Laboratory of High Magnetic Field and Ion Beam Physical Biology, Hefei Institutes of Physical Science , Chinese Academy of Sciences , Hefei , P. R. China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lui</LastName>                    <ForeName>Vivian Wai Yan</ForeName>                    <Initials>VWY</Initials>                    <AffiliationInfo>                        <Affiliation>f School of Biomedical Sciences, Faculty of Medicine , The Chinese University of Hong Kong , Hong Kong SAR.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hong</LastName>                    <ForeName>Bo</ForeName>                    <Initials>B</Initials>                    <AffiliationInfo>                        <Affiliation>a High Magnetic Field Laboratory , Chinese Academy of Sciences , Hefei , P. R. China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>c Key Laboratory of High Magnetic Field and Ion Beam Physical Biology, Hefei Institutes of Physical Science , Chinese Academy of Sciences , Hefei , P. R. China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lin</LastName>                    <ForeName>Wenchu</ForeName>                    <Initials>W</Initials>                    <AffiliationInfo>                        <Affiliation>a High Magnetic Field Laboratory , Chinese Academy of Sciences , Hefei , P. R. China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>c Key Laboratory of High Magnetic Field and Ion Beam Physical Biology, Hefei Institutes of Physical Science , Chinese Academy of Sciences , Hefei , P. R. China.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>05</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Cancer Biol Ther</MedlineTA>            <NlmUniqueID>101137842</NlmUniqueID>            <ISSNLinking>1538-4047</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">ATP1A1</Keyword>            <Keyword MajorTopicYN="N">NaCl</Keyword>            <Keyword MajorTopicYN="N">cardiac glycosides</Keyword>            <Keyword MajorTopicYN="N">digoxin</Keyword>            <Keyword MajorTopicYN="N">small cell lung cancer</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30183476</ArticleId>            <ArticleId IdType="doi">10.1080/15384047.2018.1504723</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30183374</PMID>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>05</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1530-6860</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Sep</Month>                        <Day>05</Day>                    </PubDate>                </JournalIssue>                <Title>FASEB journal : official publication of the Federation of American Societies for Experimental Biology</Title>                <ISOAbbreviation>FASEB J.</ISOAbbreviation>            </Journal>            <ArticleTitle>Brain microvascular endothelial cell exosome-mediated S100A16 up-regulation confers small-cell lung cancer cell survival in brain.</ArticleTitle>            <Pagination>                <MedlinePgn>fj201800428R</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1096/fj.201800428R</ELocationID>            <Abstract>                <AbstractText>Small cell lung cancer (SCLC) is the most aggressive histologic subtype of lung cancer, with a strong predilection for early brain metastases. Despite efforts and advances in new therapeutics for SCLC, the prognosis of patients with SCLC with brain metastases is consistently poor. Therefore, a better understanding of the mechanisms of SCLC brain metastasis is important in improving current treatments. In this study, elevated S100A16 levels were associated with SCLC brain metastases, which was a possible secondary event arising from the brain metastatic microenvironment. Using an in vitro cell coculture system, we found that the coculturing of SCLC cells with human brain microvascular endothelial cells (HBMECs) led to an increased expression of S100A16 in SCLC cells. Conversely, treatment of HBMECs with GW4869, an inhibitor of exosome release, significantly blocked this effect in the cocultured SCLC cells. Alternatively, the results from Western blot analyses and immunofluorescence indicated that the HBMEC exosomes purified by ultracentrifugation also induced the elevation and translocation from the cytoplasm to the nucleus of S100A16 in the recipient SCLC cells. The inhibition experiments demonstrated that elevated S100A16 contributed a benefit of HBMEC exosomes for the survival of the recipient SCLC cells under stress. Moreover, the elevation of S100A16 in SCLC cells prevented the loss of mitochondrial membrane potential (Δψm) and enhanced resistance to apoptosis under stressful conditions, which were determined by Annexin V/propidium iodide and JC-1 assay. Further results showed that the S100A16-mediated protective effect was caused by the presence of an important element in Δψm, prohibitin (PHB)-1, a protein in the mitochondrial inner membrane. Conversely, the delivery of PHB-1 siRNAs into S100A16 overexpressing SCLC cells weakened these protective effects. Our findings suggest that elevated S100A16 plays an active role in facilitating the survival of SCLC cells through modulating the mitochondrial function, identifying S100A16 as an important potential target in SCLC brain metastasis.-Xu, Z.-H., Miao, Z.-W., Jiang, Q.-Z., Gan, D.-X., Wei, X.-G., Xue, X.-Z., Li, J.-Q., Zheng, F., Qin, X.-X., Fang, W.-G., Chen, Y.-H., Li. B. Brain microvascular endothelial cell exosome-mediated S100A16 up-regulation confers small cell lung cancer cell survival in brain.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Xu</LastName>                    <ForeName>Zhi-Hua</ForeName>                    <Initials>ZH</Initials>                    <AffiliationInfo>                        <Affiliation>Key Laboratory of Cell Biology, Department of Developmental Biology, Ministry of Public Health, China Medical University, Shenyang, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Miao</LastName>                    <ForeName>Zi-Wei</ForeName>                    <Initials>ZW</Initials>                    <AffiliationInfo>                        <Affiliation>Key Laboratory of Cell Biology, Department of Developmental Biology, Ministry of Public Health, China Medical University, Shenyang, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Jiang</LastName>                    <ForeName>Qian-Zhu</ForeName>                    <Initials>QZ</Initials>                    <AffiliationInfo>                        <Affiliation>Key Laboratory of Cell Biology, Department of Developmental Biology, Ministry of Public Health, China Medical University, Shenyang, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Gan</LastName>                    <ForeName>Dong-Xue</ForeName>                    <Initials>DX</Initials>                    <AffiliationInfo>                        <Affiliation>Key Laboratory of Cell Biology, Department of Developmental Biology, Ministry of Public Health, China Medical University, Shenyang, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wei</LastName>                    <ForeName>Xu-Ge</ForeName>                    <Initials>XG</Initials>                    <AffiliationInfo>                        <Affiliation>Key Laboratory of Cell Biology, Department of Developmental Biology, Ministry of Public Health, China Medical University, Shenyang, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Xue</LastName>                    <ForeName>Xiao-Zhi</ForeName>                    <Initials>XZ</Initials>                    <AffiliationInfo>                        <Affiliation>Key Laboratory of Medical Cell Biology, Ministry of Education, Department of Clinical Medicine, China Medical University, Shenyang, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Li</LastName>                    <ForeName>Jue-Qi</ForeName>                    <Initials>JQ</Initials>                    <AffiliationInfo>                        <Affiliation>Key Laboratory of Medical Cell Biology, Ministry of Education, Department of Clinical Medicine, China Medical University, Shenyang, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zheng</LastName>                    <ForeName>Fei</ForeName>                    <Initials>F</Initials>                    <AffiliationInfo>                        <Affiliation>Key Laboratory of Medical Cell Biology, Ministry of Education, Department of Clinical Medicine, China Medical University, Shenyang, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Qin</LastName>                    <ForeName>Xiao-Xue</ForeName>                    <Initials>XX</Initials>                    <AffiliationInfo>                        <Affiliation>Key Laboratory of Cell Biology, Department of Developmental Biology, Ministry of Public Health, China Medical University, Shenyang, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Fang</LastName>                    <ForeName>Wen-Gang</ForeName>                    <Initials>WG</Initials>                    <AffiliationInfo>                        <Affiliation>Key Laboratory of Cell Biology, Department of Developmental Biology, Ministry of Public Health, China Medical University, Shenyang, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Chen</LastName>                    <ForeName>Yu-Hua</ForeName>                    <Initials>YH</Initials>                    <AffiliationInfo>                        <Affiliation>Key Laboratory of Cell Biology, Department of Developmental Biology, Ministry of Public Health, China Medical University, Shenyang, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Li</LastName>                    <ForeName>Bo</ForeName>                    <Initials>B</Initials>                    <AffiliationInfo>                        <Affiliation>Key Laboratory of Cell Biology, Department of Developmental Biology, Ministry of Public Health, China Medical University, Shenyang, China.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>05</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>FASEB J</MedlineTA>            <NlmUniqueID>8804484</NlmUniqueID>            <ISSNLinking>0892-6638</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">brain metastasis</Keyword>            <Keyword MajorTopicYN="N">mitochondrial membrane potential</Keyword>            <Keyword MajorTopicYN="N">prohibitin</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30183374</ArticleId>            <ArticleId IdType="doi">10.1096/fj.201800428R</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30183201</PMID>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>05</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Print">0172-780X</ISSN>                <JournalIssue CitedMedium="Print">                    <Volume>39</Volume>                    <Issue>2</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>May</Month>                        <Day>05</Day>                    </PubDate>                </JournalIssue>                <Title>Neuro endocrinology letters</Title>                <ISOAbbreviation>Neuro Endocrinol. Lett.</ISOAbbreviation>            </Journal>            <ArticleTitle>Limbic encephalitis associated with antibodies against the α-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic acid receptor: a case report.</ArticleTitle>            <Pagination>                <MedlinePgn>85-87</MedlinePgn>            </Pagination>            <Abstract>                <AbstractText>We report a case of a 51-year-old man with limbic encephalitis (LE) associated with antibodies against the α-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic acid receptor (AMPAR). The patient presented with anterograde memory loss for 2 months. Cranial magnetic resonance and electroencephalogram were normal. AMPAR antibodies were found in blood serum and cerebrospinal fluid. All other test results were unremarkable. CT scans found a tumor in the right lobus superior pulmonis. A CT-guided needle biopsy was performed and pathological results showed small cell lung cancer (SCLC). The patient was diagnosed with LE associated with AMPAR antibodies and SCLC. Three months after immunotherapy and tumor removal, patient's memory was partially restored. We recommend that AMPAR antibodies should be detected in patients with classic LE with or without tumor. Prompt treatment of the tumor and immunotherapy are important.</AbstractText>            </Abstract>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>05</Month>                <Day>05</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Sweden</Country>            <MedlineTA>Neuro Endocrinol Lett</MedlineTA>            <NlmUniqueID>8008373</NlmUniqueID>            <ISSNLinking>0172-780X</ISSNLinking>        </MedlineJournalInfo>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2017</Year>                <Month>07</Month>                <Day>23</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>01</Month>                <Day>18</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30183201</ArticleId>            <ArticleId IdType="pii">NEL390218A04</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30183078</PMID>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>05</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1097-0215</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Sep</Month>                        <Day>05</Day>                    </PubDate>                </JournalIssue>                <Title>International journal of cancer</Title>                <ISOAbbreviation>Int. J. Cancer</ISOAbbreviation>            </Journal>            <ArticleTitle>Proteogenomic systems analysis identifies targeted therapy resistance mechanisms in EGFR-mutated lung cancer.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1002/ijc.31845</ELocationID>            <Abstract>                <AbstractText>Cancer precision medicine largely relies on knowledge about genetic aberrations in tumors and next-generation-sequencing studies have shown a high mutational complexity in many cancers. Although a large number of the observed mutations is believed to be not causally linked with cancer, the functional effects of many rare mutations but also of combinations of driver mutations are often unknown. Here, we perform a systems analysis of a model of EGFR-mutated non-small cell lung cancer resistant to targeted therapy that integrates whole exome sequencing, global time-course discovery phosphoproteomics and computational modeling to identify functionally relevant molecular alterations. Our approach allows for a complexity reduction from over 2,000 genetic events potentially involved in mediating resistance to only 44 phosphoproteins and 35 topologically close genetic alterations. We perform single- and combination-drug testing against the predicted phosphoproteins and discovered that targeting of HSPB1, DBNL and AKT1 showed potent anti-proliferative effects overcoming resistance against EGFR-inhibitory therapy. Our approach may therefore be used to complement mutational profiling to identify functionally relevant molecular aberrations and propose combination therapies across cancers. This article is protected by copyright. All rights reserved.</AbstractText>                <CopyrightInformation>This article is protected by copyright. All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Treue</LastName>                    <ForeName>Denise</ForeName>                    <Initials>D</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0002-0657-5505</Identifier>                    <AffiliationInfo>                        <Affiliation>Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Pathology, Berlin, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bockmayr</LastName>                    <ForeName>Michael</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Pathology, Berlin, Germany.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Stenzinger</LastName>                    <ForeName>Albrecht</ForeName>                    <Initials>A</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0003-1001-103X</Identifier>                    <AffiliationInfo>                        <Affiliation>University of Heidelberg, Institute of Pathology, Heidelberg, Germany.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>German Cancer Consortium (DKTK), partner site Berlin, Germany.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>German Cancer Research Center (DKFZ), Heidelberg, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Heim</LastName>                    <ForeName>Daniel</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Pathology, Berlin, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hester</LastName>                    <ForeName>Svenja</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>University of Oxford, Department of Biochemistry, Oxford, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Klauschen</LastName>                    <ForeName>Frederick</ForeName>                    <Initials>F</Initials>                    <AffiliationInfo>                        <Affiliation>Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Pathology, Berlin, Germany.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>German Cancer Consortium (DKTK), partner site Berlin, Germany.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>German Cancer Research Center (DKFZ), Heidelberg, Germany.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>05</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Int J Cancer</MedlineTA>            <NlmUniqueID>0042124</NlmUniqueID>            <ISSNLinking>0020-7136</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Drug Resistance</Keyword>            <Keyword MajorTopicYN="N">Lung cancer</Keyword>            <Keyword MajorTopicYN="N">Proteomic</Keyword>            <Keyword MajorTopicYN="N">System Biology</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>02</Month>                <Day>02</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>07</Month>                <Day>02</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>07</Month>                <Day>23</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30183078</ArticleId>            <ArticleId IdType="doi">10.1002/ijc.31845</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30183073</PMID>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>05</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1097-0215</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Sep</Month>                        <Day>05</Day>                    </PubDate>                </JournalIssue>                <Title>International journal of cancer</Title>                <ISOAbbreviation>Int. J. Cancer</ISOAbbreviation>            </Journal>            <ArticleTitle>Rapalog combined with CCR4 antagonist improves anticancer vaccines efficacy.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1002/ijc.31842</ELocationID>            <Abstract>                <AbstractText>mTOR pathway inhibitors such as rapalogs represent a promising tool to induce functional memory CD8 T cells. In this study, we investigated the combination of temsirolimus with anticancer vaccines. Using various designs of cancer vaccines (short and long peptides or the B subunit of Shiga toxin as an antigen delivery vector) and tumor models (melanoma, lung and colon cancer), we showed that the administration of temsirolimus efficiently decreased tumor growth and enhanced tumor-specific CD8 T-cell responses induced by vaccination. Furthermore, tumor-specific CD8 T cells induced by the bi-therapy (vaccine + temsirolimus) exhibit phenotypic characteristics of central memory (CD127<sup>+</sup> CD62L<sup>+</sup> ) CD8 T cells compared to vaccination alone. We demonstrated that regulatory CD4 T cells (T<sub>regs</sub> ) expansion in vivo limits the efficacy of the bi-therapy by altering the antitumor CD8 T-cell responses. Finally, the use of a small molecule CCR4 antagonist to prevent T<sub>regs</sub> induction considerably improved the efficacy of the bi-therapy by enhancing CD8 T cells-mediated antitumor immunity. Taken together, this study highlights the potential interest of combining cancer vaccines with drugs that promote memory CD8 T cells and inhibit T<sub>regs</sub> . This article is protected by copyright. All rights reserved.</AbstractText>                <CopyrightInformation>This article is protected by copyright. All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Beziaud</LastName>                    <ForeName>Laurent</ForeName>                    <Initials>L</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0001-8526-3261</Identifier>                    <AffiliationInfo>                        <Affiliation>Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000, Besançon, France.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Boullerot</LastName>                    <ForeName>Laura</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000, Besançon, France.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Tran</LastName>                    <ForeName>Thi</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>INSERM UMR970, Hôpital Europeen Georges Pompidou, Paris, France.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Mansi</LastName>                    <ForeName>Laura</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000, Besançon, France.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>University Hospital of Besançon, Department of Medical Oncology, F-25000, Besançon, France.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Marie-Joseph</LastName>                    <ForeName>Elodie Lauret</ForeName>                    <Initials>EL</Initials>                    <AffiliationInfo>                        <Affiliation>Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000, Besançon, France.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ravel</LastName>                    <ForeName>Patrice</ForeName>                    <Initials>P</Initials>                    <AffiliationInfo>                        <Affiliation>IRCM - INSERM U1194, Institut de Recherche en Cancérologie de Montpellier, Equipe Bioinformatique et biologie des systèmes du cancer, Montpellier, France.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Johannes</LastName>                    <ForeName>Ludger</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Institut Curie, PSL Research University, Chemical Biology of Membranes and Therapeutic Delivery Unit, INSERM U1143, CNRS UMR3666, F-75248, Paris, France.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bayry</LastName>                    <ForeName>Jagadeesh</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>INSERM; Centre de Recherche des Cordeliers; Sorbonne Université; Université Paris Descartes, Sorbonne Paris Cité, F-75006, Paris, France.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Tartour</LastName>                    <ForeName>Eric</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>INSERM UMR970, Hôpital Europeen Georges Pompidou, Paris, France.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Biological Immunology, Assistance Publique-Hôpitaux de Paris, Paris, France.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>University Paris Descartes, Sorbonne Paris Cite, Paris, France.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Adotévi</LastName>                    <ForeName>Olivier</ForeName>                    <Initials>O</Initials>                    <AffiliationInfo>                        <Affiliation>Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000, Besançon, France.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>University Hospital of Besançon, Department of Medical Oncology, F-25000, Besançon, France.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>05</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Int J Cancer</MedlineTA>            <NlmUniqueID>0042124</NlmUniqueID>            <ISSNLinking>0020-7136</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">CCR4 antagonist</Keyword>            <Keyword MajorTopicYN="N">CD8 T cells</Keyword>            <Keyword MajorTopicYN="N">Rapalog</Keyword>            <Keyword MajorTopicYN="N">cancer vaccine</Keyword>            <Keyword MajorTopicYN="N">regulatory CD4 T cells</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>03</Month>                <Day>24</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>07</Month>                <Day>28</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>08</Month>                <Day>09</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30183073</ArticleId>            <ArticleId IdType="doi">10.1002/ijc.31842</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30182373</PMID>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>05</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1098-2744</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Sep</Month>                        <Day>04</Day>                    </PubDate>                </JournalIssue>                <Title>Molecular carcinogenesis</Title>                <ISOAbbreviation>Mol. Carcinog.</ISOAbbreviation>            </Journal>            <ArticleTitle>EGCG inhibits CSC-like properties through targeting miR-485/CD44 axis in A549-cisplatin resistant cells.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1002/mc.22901</ELocationID>            <Abstract>                <AbstractText>Non-small cell lung cancer (NSCLC) remains one of the most aggressive tumors with low life expectancy worldwide. The existence of cancer stem cells (CSCs) contributes to the failure of cancer treatment resulted from drug resistance. Altered microRNA expression has been observed in human tumors due to its role in tumor growth, progression and metastasis. Hence, the aim of our present study was to investigate the effects of miR-485 on the CSC-like traits in NSCLC A549-cisplatin resistant cells and concentrate on the underlying molecular mechanism. It was found that CSC-like phenotypes were much more enriched in A549/cisplatin (A549/CDDP) cells compared to A549-parental cells. In addition, we observed that miR-485 was greatly decreased in A549/CDDP cells and miR-485 overexpression was able to decrease the stemness of A549/DDP cells. Meanwhile, epigallocatechin-3-gallate (EGCG), a green tea polyphenol which has been identified as an effective anticancer compound was able to increase miR-485 expression dose-dependently in A549/CDDP cells. Inhibitors of miR-485 remarkably increased CSC-like phenotypes, which could be reversed by indicated doses of EGCG. Moreover, CD44 was predicted as downstream target of miR-485 and the correlation between them was validated by performing dual-luciferase reporter assay and RNA immunoprecipitation (RIP) assay. Subsequently, in vivo experiments were employed to confirm that EGCG restrained CSC-like characteristics by increasing miR-485 and decreasing CD44 expression. Taken together, it was implied that stemness features and CSC population were suppressed by EGCG-modulated miR-485/CD44 axis in A549/CDDP cells. This article is protected by copyright. All rights reserved.</AbstractText>                <CopyrightInformation>This article is protected by copyright. All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Jiang</LastName>                    <ForeName>Pan</ForeName>                    <Initials>P</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Nutrition and Food Hygiene, Key Laboratory of Toxicology, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Xu</LastName>                    <ForeName>Chuyue</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Nutrition and Food Hygiene, Key Laboratory of Toxicology, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Chen</LastName>                    <ForeName>Lijun</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Nutrition and Food Hygiene, Key Laboratory of Toxicology, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Chen</LastName>                    <ForeName>Aochang</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Nutrition and Food Hygiene, Key Laboratory of Toxicology, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wu</LastName>                    <ForeName>Xiaoyue</ForeName>                    <Initials>X</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Nutrition and Food Hygiene, Key Laboratory of Toxicology, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhou</LastName>                    <ForeName>Ming</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Nutrition and Food Hygiene, Key Laboratory of Toxicology, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Haq</LastName>                    <ForeName>Ijaz Ul</ForeName>                    <Initials>IU</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Nutrition and Food Hygiene, Key Laboratory of Toxicology, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Mariyam</LastName>                    <ForeName>Zahula</ForeName>                    <Initials>Z</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Nutrition and Food Hygiene, Key Laboratory of Toxicology, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Feng</LastName>                    <ForeName>Qing</ForeName>                    <Initials>Q</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Nutrition and Food Hygiene, Key Laboratory of Toxicology, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu, China.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>04</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Mol Carcinog</MedlineTA>            <NlmUniqueID>8811105</NlmUniqueID>            <ISSNLinking>0899-1987</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">A549/CDDP</Keyword>            <Keyword MajorTopicYN="N">CD44</Keyword>            <Keyword MajorTopicYN="N">EGCG</Keyword>            <Keyword MajorTopicYN="N">cancer stem cells</Keyword>            <Keyword MajorTopicYN="N">miR-485</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>05</Month>                <Day>29</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>08</Month>                <Day>24</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>08</Month>                <Day>31</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30182373</ArticleId>            <ArticleId IdType="doi">10.1002/mc.22901</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">        <PMID Version="1">30181949</PMID>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>05</Day>        </DateRevised>        <Article PubModel="Electronic-eCollection">            <Journal>                <ISSN IssnType="Print">2213-0071</ISSN>                <JournalIssue CitedMedium="Print">                    <Volume>25</Volume>                    <PubDate>                        <Year>2018</Year>                    </PubDate>                </JournalIssue>                <Title>Respiratory medicine case reports</Title>                <ISOAbbreviation>Respir Med Case Rep</ISOAbbreviation>            </Journal>            <ArticleTitle>Actinomyces viscosus causing disseminated disease in a patient on methotrexate.</ArticleTitle>            <Pagination>                <MedlinePgn>158-160</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.rmcr.2018.08.009</ELocationID>            <Abstract>                <AbstractText>Actinomycosis is an uncommon infectious disease caused predominantly by Actinomyces israelii. Actinomycosis usually involves the cervicofacial, thoracic, abdominal, and pelvic region, dissemination is uncommon. Actinomyces viscosus are commensal organisms that make up the normal flora of the oropharynx of humans and has rarely been reported to cause disease. Here, we report a unique case of disseminated actinomycosis with lung and brain lesions caused by Actinomyces viscosus resembling lung cancer with metastasis in a 74 year old male. Cultures from skin lesions confirmed A. viscosus. Although the patient was immunocompromised, antibiotic treatment with a penicillin-based regimen was effective.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Habib</LastName>                    <ForeName>Saad</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Department- Internal Medicine, Staten Island University Hospital, 475 Seaview Avenue, Staten Island, NY, 10304, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Siddiqui</LastName>                    <ForeName>Abdul Hasan</ForeName>                    <Initials>AH</Initials>                    <AffiliationInfo>                        <Affiliation>Staten Island University Hospital, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Azam</LastName>                    <ForeName>Mohammed</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Staten Island University Hospital, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Siddiqui</LastName>                    <ForeName>Faraz</ForeName>                    <Initials>F</Initials>                    <AffiliationInfo>                        <Affiliation>Staten Island University Hospital, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Chalhoub</LastName>                    <ForeName>Michel</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Staten Island University Hospital, USA.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>08</Month>                <Day>25</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>Respir Med Case Rep</MedlineTA>            <NlmUniqueID>101604463</NlmUniqueID>            <ISSNLinking>2213-0071</ISSNLinking>        </MedlineJournalInfo>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>08</Month>                <Day>08</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>08</Month>                <Day>13</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>08</Month>                <Day>13</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>1</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30181949</ArticleId>            <ArticleId IdType="doi">10.1016/j.rmcr.2018.08.009</ArticleId>            <ArticleId IdType="pii">S2213-0071(18)30224-7</ArticleId>            <ArticleId IdType="pmc">PMC6121156</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">        <PMID Version="1">30181829</PMID>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>05</Day>        </DateRevised>        <Article PubModel="Electronic-eCollection">            <Journal>                <ISSN IssnType="Print">2000-9666</ISSN>                <JournalIssue CitedMedium="Print">                    <Volume>8</Volume>                    <Issue>4</Issue>                    <PubDate>                        <Year>2018</Year>                    </PubDate>                </JournalIssue>                <Title>Journal of community hospital internal medicine perspectives</Title>                <ISOAbbreviation>J Community Hosp Intern Med Perspect</ISOAbbreviation>            </Journal>            <ArticleTitle>Brain metastasis in colorectal cancer presenting as refractory hypertension.</ArticleTitle>            <Pagination>                <MedlinePgn>215-219</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1080/20009666.2018.1490138</ELocationID>            <Abstract>                <AbstractText><b>Background</b>: Brain metastasis (BM) from colorectal cancer (CRC) is rare with the incidence ranging from 0.6% to 3.2%. There is also an increased incidence of BM with rectal primaries and is consistent with this patient's presentation. Overall, there is scarce literature on the symptoms of patients who present with CRC BMs. <b>Objectives</b>: We present a case of brain metastasis in colorectal cancer presenting with hypertensive urgency and severe headache. <b>Methods and results</b>: This case highlights that neurological deficits are not necessary for BMs in patients with CRC and summarizes and reviews the associated literature regarding BM in CRC. A 57-year-old female with a past medical history of recently diagnosed stage IV moderately differentiated distal rectal adenocarcinoma with liver and lung metastasis was admitted with the primary complaint of hypertensive urgency, severe headache, intractable nausea and vomiting, and diarrhea. Magnetic resonance imaging brain showed a left cerebellar lesion measuring 3.6 × 3.2 × 2.9 cm, ipsilateral transtentorial herniation, and obliteration of the fourth ventricle. The patient was started on steroids and transferred for an urgent neurosurgical intervention to a tertiary care center. <b>Conclusions</b>: Even though BMs are rare in CRC, clinicians should have a high index of suspicion with complaints like hypertensive urgency, headache, nausea, vomiting, vertigo, and blurring of vision triggering imaging studies to rule out BM. The approach to BM has become increasingly individualized as surgical and radiosurgical therapies have continued to evolve <b>Abbreviations</b>: CRC: Colorectal cancer; BM: Brain metastasis; FOLFOX: Folinic acid, fluorouracil and oxaliplatin; CT: Computed tomography; IV: Intravenous; PO: By mouth; BAER: Brain auditory evoked response hearing testing; SSEP's: Somatosensory evoked potentials; BMFI: Brain metastasis free interval; WBRT: Whole-brain radiation therapy; SRS: Stereotactic radiosurgery.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Hassan</LastName>                    <ForeName>Syed Moin</ForeName>                    <Initials>SM</Initials>                    <Identifier Source="ORCID">0000-0002-1544-3280</Identifier>                    <AffiliationInfo>                        <Affiliation>Internal Medicine Resident, Oak Hill Hospital, Brooksville, FL, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Mubarik</LastName>                    <ForeName>Ateeq</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Internal Medicine Resident, Oak Hill Hospital, Brooksville, FL, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Muddassir</LastName>                    <ForeName>Salman</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Internal Medicine Resident, Oak Hill Hospital, Brooksville, FL, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Haq</LastName>                    <ForeName>Furqan</ForeName>                    <Initials>F</Initials>                    <AffiliationInfo>                        <Affiliation>Hospital Corporation America (HCA), West Florida Division, Tampa, FL, USA.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>08</Month>                <Day>23</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>J Community Hosp Intern Med Perspect</MedlineTA>            <NlmUniqueID>101601396</NlmUniqueID>            <ISSNLinking>2000-9666</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Brain metastasis</Keyword>            <Keyword MajorTopicYN="N">colorectal cancer</Keyword>            <Keyword MajorTopicYN="N">hypertensive urgency</Keyword>            <Keyword MajorTopicYN="N">mass effect</Keyword>            <Keyword MajorTopicYN="N">neurosurgery</Keyword>            <Keyword MajorTopicYN="N">solitary lesion</Keyword>            <Keyword MajorTopicYN="N">stereotactic radiosurgery</Keyword>            <Keyword MajorTopicYN="N">whole-brain radiotherapy</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>03</Month>                <Day>18</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>06</Month>                <Day>12</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>1</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30181829</ArticleId>            <ArticleId IdType="doi">10.1080/20009666.2018.1490138</ArticleId>            <ArticleId IdType="pii">1490138</ArticleId>            <ArticleId IdType="pmc">PMC6116300</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">        <PMID Version="1">30181806</PMID>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>05</Day>        </DateRevised>        <Article PubModel="Electronic-eCollection">            <Journal>                <ISSN IssnType="Electronic">1949-2553</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>9</Volume>                    <Issue>63</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Aug</Month>                        <Day>14</Day>                    </PubDate>                </JournalIssue>                <Title>Oncotarget</Title>                <ISOAbbreviation>Oncotarget</ISOAbbreviation>            </Journal>            <ArticleTitle>Somatic genome alterations in relation to age in lung squamous cell carcinoma.</ArticleTitle>            <Pagination>                <MedlinePgn>32161-32172</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.18632/oncotarget.25848</ELocationID>            <Abstract>                <AbstractText>Lung squamous cell carcinoma (LUSC) is the most common cause of global cancer-related mortality and the major risk factors is smoking consumption. By analyzing ∼500 LUSC samples from The Cancer Genome Atlas, we detected a higher mutational burden as well as a higher level of methylation changes in younger patients. The SNPs mutational profiling showed enrichments of smoking-related signature 4 and defective DNA mismatch repair (MMR)-related signature 6 in younger patients, while the defective DNA MMR signature 26 was enriched among older patients. Furthermore, gene set enrichment analysis was performed in order to explore functional effect of somatic alterations in relation to patient age. Extracellular Matrix-Receptor Interaction, Nucleotide Excision Repair and Axon Guidance seem crucial disrupted pathways in younger patients. We hypothesize that a higher sensitivity to smoking-related damages and the enrichment of defective DNA MMR related mutations may contribute to the higher mutational burden of younger patients. The two distinct age-related defective DNA MMR signatures 6 and 26 might be crucial mutational patterns in LUSC tumorigenesis which may develop distinct phenotypes. Our study provides indications of age-dependent differences in mutational backgrounds (SNPs and CNVs) as well as epigenetic patterns that might be relevant for age adjusted treatment approaches.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Meucci</LastName>                    <ForeName>Stefano</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Charité Comprehensive Cancer Center, Charité University Hospital, Berlin, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Keilholz</LastName>                    <ForeName>Ulrich</ForeName>                    <Initials>U</Initials>                    <AffiliationInfo>                        <Affiliation>Charité Comprehensive Cancer Center, Charité University Hospital, Berlin, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Heim</LastName>                    <ForeName>Daniel</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>Institut für Pathologie, Charité University Hospital, Berlin, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Klauschen</LastName>                    <ForeName>Frederick</ForeName>                    <Initials>F</Initials>                    <AffiliationInfo>                        <Affiliation>Institut für Pathologie, Charité University Hospital, Berlin, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Cacciatore</LastName>                    <ForeName>Stefano</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Imperial College Parturition Research Group, Division of the Institute of Reproductive and Developmental Biology, Imperial College London, London, England, UK.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>International Centre for Genetic Engineering and Biotechnology, Cancer Genomics Group, Cape Town, South Africa.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>08</Month>                <Day>14</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Oncotarget</MedlineTA>            <NlmUniqueID>101532965</NlmUniqueID>            <ISSNLinking>1949-2553</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">aging</Keyword>            <Keyword MajorTopicYN="N">copy number variations</Keyword>            <Keyword MajorTopicYN="N">lung squamous cell carcinoma</Keyword>            <Keyword MajorTopicYN="N">methylation</Keyword>            <Keyword MajorTopicYN="N">somatic mutations</Keyword>        </KeywordList>        <CoiStatement>CONFLICTS OF INTEREST There is no conflicts of interest that I should disclose.</CoiStatement>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>01</Month>                <Day>19</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>07</Month>                <Day>12</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>1</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30181806</ArticleId>            <ArticleId IdType="doi">10.18632/oncotarget.25848</ArticleId>            <ArticleId IdType="pii">25848</ArticleId>            <ArticleId IdType="pmc">PMC6114948</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">        <PMID Version="1">30181523</PMID>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>05</Day>        </DateRevised>        <Article PubModel="Electronic">            <Journal>                <ISSN IssnType="Print">2072-6694</ISSN>                <JournalIssue CitedMedium="Print">                    <Volume>10</Volume>                    <Issue>9</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Sep</Month>                        <Day>04</Day>                    </PubDate>                </JournalIssue>                <Title>Cancers</Title>                <ISOAbbreviation>Cancers (Basel)</ISOAbbreviation>            </Journal>            <ArticleTitle>Surgical Resection Versus Stereotactic Body Radiation Therapy for Stage I NSCLC: Can Randomized Trials Provide the Solution?</ArticleTitle>            <ELocationID EIdType="pii" ValidYN="Y">E310</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.3390/cancers10090310</ELocationID>            <Abstract>                <AbstractText>Surgical resection has traditionally been considered the standard of care for patients with stage I non-small cell lung cancer (NSCLC). With the introduction of stereotactic radiation body therapy (SBRT), there is now a viable option for medically inoperable patients with stage I NSCLC. The effectiveness of SBRT in patients with stage I disease but at elevated surgical risk is unknown. Multiple randomized controlled trials (RCTs) have been attempted to compare surgical resection and SBRT in this population, but have been aborted due to poor patient enrollment. Despite these failures, there still remains a push for more RCTs. In this commentary, we review the challenges that RCTs face in their ability to appropriately compare these two therapies.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Subramanian</LastName>                    <ForeName>Melanie P</ForeName>                    <Initials>MP</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Cardiothoracic Surgery, Washington University School of Medicine, 660 S Euclid Ave, St. Louis, MO 63110, USA. m.p.subramanian@email.wustl.edu.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Meyers</LastName>                    <ForeName>Bryan F</ForeName>                    <Initials>BF</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Cardiothoracic Surgery, Washington University School of Medicine, 660 S Euclid Ave, St. Louis, MO 63110, USA. meyersb@wustl.edu.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>04</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Switzerland</Country>            <MedlineTA>Cancers (Basel)</MedlineTA>            <NlmUniqueID>101526829</NlmUniqueID>            <ISSNLinking>2072-6694</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">NSCLC</Keyword>            <Keyword MajorTopicYN="N">SBRT</Keyword>            <Keyword MajorTopicYN="N">lobectomy</Keyword>            <Keyword MajorTopicYN="N">randomized controlled trials</Keyword>            <Keyword MajorTopicYN="N">sublobar resection</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>07</Month>                <Day>18</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>08</Month>                <Day>28</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>08</Month>                <Day>30</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>1</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30181523</ArticleId>            <ArticleId IdType="pii">cancers10090310</ArticleId>            <ArticleId IdType="doi">10.3390/cancers10090310</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">        <PMID Version="1">30181510</PMID>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>05</Day>        </DateRevised>        <Article PubModel="Electronic">            <Journal>                <ISSN IssnType="Print">2072-6694</ISSN>                <JournalIssue CitedMedium="Print">                    <Volume>10</Volume>                    <Issue>9</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Sep</Month>                        <Day>04</Day>                    </PubDate>                </JournalIssue>                <Title>Cancers</Title>                <ISOAbbreviation>Cancers (Basel)</ISOAbbreviation>            </Journal>            <ArticleTitle>Cariprazine, A Dopamine D₂/D₃ Receptor Partial Agonist, Modulates ABCG2-Mediated Multidrug Resistance in Cancer.</ArticleTitle>            <ELocationID EIdType="pii" ValidYN="Y">E308</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.3390/cancers10090308</ELocationID>            <Abstract>                <AbstractText>Multidrug resistance (MDR) is a continuing clinical problem that limits the efficacy of chemotherapy in cancer. The over expression of the ATP-binding cassette (ABC) family G2 (ABCG2) transporter is one of the main mechanisms that mediates MDR in cancer. Molecular modeling data indicated that cariprazine, a dopamine D₂/D₃ receptor partial agonist, had a significant binding affinity for ABCG2 transporter with a Glide XP score of -6.515. Therefore, in this in vitro study, we determined the effect of cariprazine on MDR resulting from the overexpression of ABCG2 transporters. Alone, cariprazine, at concentrations up to 20 μM, did not significantly decrease cell viability. Cariprazine, at concentrations ranging from 1 to 10 μM, did not significantly alter the cytotoxicity of mitoxantrone (MX) in the parental non-small cell cancer cell line, H460 and colon cancer cell S1. However, cariprazine (1⁻20 μM) significantly enhanced the efficacy of ABCG2 substrate antineoplastic drug MX in the ABCG2-overexpressing MDR cell line, H460-MX20 and S1M1-80, by reducing the resistance fold from 28 to 1 and from 93 to 1.33, respectively. Cariprazine, in a concentration-dependent (1⁻20 μM), significantly increased the intracellular accumulation of Rhodamine 123 in S1M1-80. Interestingly, 10 or 20 μM of cariprazine significantly decreased the expression levels of the ABCG2 protein in the colon and lung cancer cell lines, suggesting that cariprazine inhibits both the function and expression of ABCG2 transporters at nontoxic concentrations. Overall, our results suggest that cariprazine, via several distinct mechanisms, can resensitize resistant cancer cells to mitoxantrone.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Hussein</LastName>                    <ForeName>Noor</ForeName>                    <Initials>N</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pharmacology and Experimental Therapeutics, College of Pharmacy &amp; Pharmaceutical Sciences, University of Toledo, Toledo, OH 43614, USA. noor.hussein@rockets.utoledo.edu.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ashby</LastName>                    <ForeName>Charles R</ForeName>                    <Initials>CR</Initials>                    <Suffix>Jr</Suffix>                    <AffiliationInfo>                        <Affiliation>Department of Pharmaceutical Sciences, College of Pharmacy, St. John's University, Queens, NY 11439, USA. cnsratdoc@optonline.net.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Amawi</LastName>                    <ForeName>Haneen</ForeName>                    <Initials>H</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pharmacology and Experimental Therapeutics, College of Pharmacy &amp; Pharmaceutical Sciences, University of Toledo, Toledo, OH 43614, USA. haneen.amawi@rockets.utoledo.edu.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Nyinawabera</LastName>                    <ForeName>Angelique</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pharmacology and Experimental Therapeutics, College of Pharmacy &amp; Pharmaceutical Sciences, University of Toledo, Toledo, OH 43614, USA. angelique.nyinawabera@rockets.utoledo.edu.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Vij</LastName>                    <ForeName>Atul</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pharmacology and Experimental Therapeutics, College of Pharmacy &amp; Pharmaceutical Sciences, University of Toledo, Toledo, OH 43614, USA. atulvij1994@yahoo.com.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Khare</LastName>                    <ForeName>Vishwa M</ForeName>                    <Initials>VM</Initials>                    <AffiliationInfo>                        <Affiliation>Cell and Developmental Biology, School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. khare_vm@yahoo.com.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Karthikeyan</LastName>                    <ForeName>Chandrabose</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pharmacy, Indira Gandhi National Tribal University, Lalpur, Amarkantak, MP 484887, India. karthinobel@gmail.com.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Tiwari</LastName>                    <ForeName>Amit K</ForeName>                    <Initials>AK</Initials>                    <Identifier Source="ORCID">0000-0002-7427-7155</Identifier>                    <AffiliationInfo>                        <Affiliation>Department of Pharmacology and Experimental Therapeutics, College of Pharmacy &amp; Pharmaceutical Sciences, University of Toledo, Toledo, OH 43614, USA. amit.tiwari@utoledo.edu.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>04</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Switzerland</Country>            <MedlineTA>Cancers (Basel)</MedlineTA>            <NlmUniqueID>101526829</NlmUniqueID>            <ISSNLinking>2072-6694</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">ABCG2</Keyword>            <Keyword MajorTopicYN="N">Cariprazine</Keyword>            <Keyword MajorTopicYN="N">Colon cancer</Keyword>            <Keyword MajorTopicYN="N">Dopamine D3-preferring D2/D3 receptor partial</Keyword>            <Keyword MajorTopicYN="N">Lung cancer</Keyword>            <Keyword MajorTopicYN="N">Multidrug resistance</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>07</Month>                <Day>20</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>08</Month>                <Day>13</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>08</Month>                <Day>27</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>1</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30181510</ArticleId>            <ArticleId IdType="pii">cancers10090308</ArticleId>            <ArticleId IdType="doi">10.3390/cancers10090308</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="In-Data-Review" Owner="NLM">        <PMID Version="1">30181417</PMID>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>05</Day>        </DateRevised>        <Article PubModel="Print">            <Journal>                <ISSN IssnType="Electronic">1540-1413</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>16</Volume>                    <Issue>9</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Sep</Month>                    </PubDate>                </JournalIssue>                <Title>Journal of the National Comprehensive Cancer Network : JNCCN</Title>                <ISOAbbreviation>J Natl Compr Canc Netw</ISOAbbreviation>            </Journal>            <ArticleTitle>Use of Inpatient Palliative Care Services in Patients With Advanced Cancer Receiving Critical Care Therapies.</ArticleTitle>            <Pagination>                <MedlinePgn>1055-1064</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.6004/jnccn.2018.7039</ELocationID>            <Abstract>                <AbstractText><b>Background:</b> Invasive mechanical ventilation (IMV), dialysis for acute kidney failure, and other critical care therapies (CCTs) are associated with a high risk for complications in patients with metastatic cancer. Inpatient palliative care (IPC) can assist in assessing patients' preferences for life-prolonging treatment at the end of life. This study investigated the use pattern of IPC, outcomes (in-hospital mortality, length of stay [LOS], discharge destination, and cost of care), and predictors of IPC use in patients with metastatic cancer who received CCTs. We hypothesized that IPC services are underused in this cohort. <b>Methods:</b> In this retrospective cohort study, we used the 2010 California State Inpatient Databases to identify adults with metastatic cancer who received CCTs that are common and reliably coded (IMV, tracheostomy, percutaneous endoscopic gastrostomy tube, dialysis for acute kidney failure, and total parenteral nutrition). We determined IPC use in all patients, in those who received IMV, and across 4 cancer subtypes (lung, breast, colorectal, and genitourinary). Outcomes were assessed based on IPC use. Multivariable analyses were used to investigate factors associated with IPC use. <b>Results:</b> We identified 5,862 hospitalizations, 19.8% of which used IPC services. IPC use varied across cancer subtypes (lung, 28.3%; breast, 22.4%; colorectal, 12.8%; genitourinary, 16.1%; <i>P</i>&lt;.01). Patients who received and did not receive IPC services had high in-hospital mortality rates (63.9% and 29.8%, respectively), and costs of care and LOS were lower in survivors who received IPC compared with those who did not. Predictors of IPC use were lung cancer (vs colorectal or genitourinary cancer), higher comorbidity score, do-not-resuscitate status on admission or within 24 hours of admission, infections (vs cancer-related diagnoses), and higher hospital bed count. <b>Conclusions:</b> Use of IPC was low in the cohort who received CCTs with poor outcomes, although data on outpatient palliative care services is lacking. Predictors of IPC use may be used to identify patients who may benefit from these services.</AbstractText>                <CopyrightInformation>Copyright © 2018 by the National Comprehensive Cancer Network.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Loh</LastName>                    <ForeName>Kah Poh</ForeName>                    <Initials>KP</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Hematology/Oncology, James P. Wilmot Cancer Institute, University of Rochester/Strong Memorial Hospital, Rochester, New York; Department of Internal Medicine, and Institute for Healthcare Delivery and Population Science, University of Massachusetts Medical School-Baystate, Springfield, Massachusetts; and Department of Biostatistics and Epidemiology, University of Massachusetts, Amherst, Massachusetts.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Abdallah</LastName>                    <ForeName>Maya</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Hematology/Oncology, James P. Wilmot Cancer Institute, University of Rochester/Strong Memorial Hospital, Rochester, New York; Department of Internal Medicine, and Institute for Healthcare Delivery and Population Science, University of Massachusetts Medical School-Baystate, Springfield, Massachusetts; and Department of Biostatistics and Epidemiology, University of Massachusetts, Amherst, Massachusetts.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Shieh</LastName>                    <ForeName>Meng-Shiou</ForeName>                    <Initials>MS</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Hematology/Oncology, James P. Wilmot Cancer Institute, University of Rochester/Strong Memorial Hospital, Rochester, New York; Department of Internal Medicine, and Institute for Healthcare Delivery and Population Science, University of Massachusetts Medical School-Baystate, Springfield, Massachusetts; and Department of Biostatistics and Epidemiology, University of Massachusetts, Amherst, Massachusetts.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Stefan</LastName>                    <ForeName>Mihaela S</ForeName>                    <Initials>MS</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Hematology/Oncology, James P. Wilmot Cancer Institute, University of Rochester/Strong Memorial Hospital, Rochester, New York; Department of Internal Medicine, and Institute for Healthcare Delivery and Population Science, University of Massachusetts Medical School-Baystate, Springfield, Massachusetts; and Department of Biostatistics and Epidemiology, University of Massachusetts, Amherst, Massachusetts.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Division of Hematology/Oncology, James P. Wilmot Cancer Institute, University of Rochester/Strong Memorial Hospital, Rochester, New York; Department of Internal Medicine, and Institute for Healthcare Delivery and Population Science, University of Massachusetts Medical School-Baystate, Springfield, Massachusetts; and Department of Biostatistics and Epidemiology, University of Massachusetts, Amherst, Massachusetts.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Pekow</LastName>                    <ForeName>Penelope S</ForeName>                    <Initials>PS</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Hematology/Oncology, James P. Wilmot Cancer Institute, University of Rochester/Strong Memorial Hospital, Rochester, New York; Department of Internal Medicine, and Institute for Healthcare Delivery and Population Science, University of Massachusetts Medical School-Baystate, Springfield, Massachusetts; and Department of Biostatistics and Epidemiology, University of Massachusetts, Amherst, Massachusetts.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Division of Hematology/Oncology, James P. Wilmot Cancer Institute, University of Rochester/Strong Memorial Hospital, Rochester, New York; Department of Internal Medicine, and Institute for Healthcare Delivery and Population Science, University of Massachusetts Medical School-Baystate, Springfield, Massachusetts; and Department of Biostatistics and Epidemiology, University of Massachusetts, Amherst, Massachusetts.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lindenauer</LastName>                    <ForeName>Peter K</ForeName>                    <Initials>PK</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Hematology/Oncology, James P. Wilmot Cancer Institute, University of Rochester/Strong Memorial Hospital, Rochester, New York; Department of Internal Medicine, and Institute for Healthcare Delivery and Population Science, University of Massachusetts Medical School-Baystate, Springfield, Massachusetts; and Department of Biostatistics and Epidemiology, University of Massachusetts, Amherst, Massachusetts.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Division of Hematology/Oncology, James P. Wilmot Cancer Institute, University of Rochester/Strong Memorial Hospital, Rochester, New York; Department of Internal Medicine, and Institute for Healthcare Delivery and Population Science, University of Massachusetts Medical School-Baystate, Springfield, Massachusetts; and Department of Biostatistics and Epidemiology, University of Massachusetts, Amherst, Massachusetts.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Mohile</LastName>                    <ForeName>Supriya G</ForeName>                    <Initials>SG</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Hematology/Oncology, James P. Wilmot Cancer Institute, University of Rochester/Strong Memorial Hospital, Rochester, New York; Department of Internal Medicine, and Institute for Healthcare Delivery and Population Science, University of Massachusetts Medical School-Baystate, Springfield, Massachusetts; and Department of Biostatistics and Epidemiology, University of Massachusetts, Amherst, Massachusetts.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Babu</LastName>                    <ForeName>Dilip</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Hematology/Oncology, James P. Wilmot Cancer Institute, University of Rochester/Strong Memorial Hospital, Rochester, New York; Department of Internal Medicine, and Institute for Healthcare Delivery and Population Science, University of Massachusetts Medical School-Baystate, Springfield, Massachusetts; and Department of Biostatistics and Epidemiology, University of Massachusetts, Amherst, Massachusetts.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lagu</LastName>                    <ForeName>Tara</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Hematology/Oncology, James P. Wilmot Cancer Institute, University of Rochester/Strong Memorial Hospital, Rochester, New York; Department of Internal Medicine, and Institute for Healthcare Delivery and Population Science, University of Massachusetts Medical School-Baystate, Springfield, Massachusetts; and Department of Biostatistics and Epidemiology, University of Massachusetts, Amherst, Massachusetts.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Division of Hematology/Oncology, James P. Wilmot Cancer Institute, University of Rochester/Strong Memorial Hospital, Rochester, New York; Department of Internal Medicine, and Institute for Healthcare Delivery and Population Science, University of Massachusetts Medical School-Baystate, Springfield, Massachusetts; and Department of Biostatistics and Epidemiology, University of Massachusetts, Amherst, Massachusetts.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>J Natl Compr Canc Netw</MedlineTA>            <NlmUniqueID>101162515</NlmUniqueID>            <ISSNLinking>1540-1405</ISSNLinking>        </MedlineJournalInfo>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2017</Year>                <Month>12</Month>                <Day>08</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>04</Month>                <Day>26</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30181417</ArticleId>            <ArticleId IdType="pii">16/9/1055</ArticleId>            <ArticleId IdType="doi">10.6004/jnccn.2018.7039</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="In-Data-Review" Owner="NLM">        <PMID Version="1">30181415</PMID>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>05</Day>        </DateRevised>        <Article PubModel="Print">            <Journal>                <ISSN IssnType="Electronic">1540-1413</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>16</Volume>                    <Issue>9</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Sep</Month>                    </PubDate>                </JournalIssue>                <Title>Journal of the National Comprehensive Cancer Network : JNCCN</Title>                <ISOAbbreviation>J Natl Compr Canc Netw</ISOAbbreviation>            </Journal>            <ArticleTitle>Targeting <i>BRAF</i> Mutations in High-Grade Neuroendocrine Carcinoma of the Colon.</ArticleTitle>            <Pagination>                <MedlinePgn>1035-1040</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.6004/jnccn.2018.7043</ELocationID>            <Abstract>                <AbstractText>Mutations in the RAS/RAF/MEK/ERK pathway leading to constitutive activation and uncontrolled cellular growth have been identified in various human malignancies, making this pathway a target for potential therapeutics. The activating <i>BRAF</i><sup>V600E</sup> mutation is one well-characterized oncogenic mutation that has been described and targeted with clinical success in various malignancies, including melanoma and hairy cell leukemia. Although <i>BRAF</i>-directed treatments have yielded clinical benefit in a subset of tumor types, such as melanoma, thyroid cancer, and lung cancer, BRAF inhibition fails to confer a clinical benefit in colon cancer. Identification of patients for whom BRAF inhibition may produce clinically meaningful outcomes is imperative. The incidence of <i>BRAF</i> mutations in neuroendocrine carcinoma (NEC) is estimated to be 5% to 10%. A recent case series demonstrated benefit in targeting the <i>BRAF</i><sup>V600E</sup> mutation in metastatic high-grade rectal NECs. Combination BRAF and MEK inhibition is known to yield improved outcomes compared with BRAF inhibition alone in melanoma. This report presents 2 patients with high-grade colorectal NECs who had different responses to treatment with combined BRAF/MEK inhibition after experiencing disease progression through first-line platinum-based chemotherapy. One patient experienced an excellent initial response to therapy before ultimately experiencing progression, and in the other patient initially had stable disease before eventually experiencing progression. These cases highlight the complicated role <i>BRAF</i> mutations play in gastrointestinal NECs, and the need for further research to identify not only patients who may benefit from <i>BRAF</i>-directed therapies but also strategies to avoid development of resistance.</AbstractText>                <CopyrightInformation>Copyright © 2018 by the National Comprehensive Cancer Network.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Burkart</LastName>                    <ForeName>Jarred</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Medical Oncology, Department of Internal Medicine, and Division of Surgical Oncology, Department of Surgery, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio; and Division of Medical Oncology, Department of Internal Medicine, Stanford University, Stanford, California.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Owen</LastName>                    <ForeName>Dwight</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Medical Oncology, Department of Internal Medicine, and Division of Surgical Oncology, Department of Surgery, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio; and Division of Medical Oncology, Department of Internal Medicine, Stanford University, Stanford, California.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Shah</LastName>                    <ForeName>Manisha H</ForeName>                    <Initials>MH</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Medical Oncology, Department of Internal Medicine, and Division of Surgical Oncology, Department of Surgery, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio; and Division of Medical Oncology, Department of Internal Medicine, Stanford University, Stanford, California.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Abdel-Misih</LastName>                    <ForeName>Sherif R Z</ForeName>                    <Initials>SRZ</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Medical Oncology, Department of Internal Medicine, and Division of Surgical Oncology, Department of Surgery, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio; and Division of Medical Oncology, Department of Internal Medicine, Stanford University, Stanford, California.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Roychowdhury</LastName>                    <ForeName>Sameek</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Medical Oncology, Department of Internal Medicine, and Division of Surgical Oncology, Department of Surgery, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio; and Division of Medical Oncology, Department of Internal Medicine, Stanford University, Stanford, California.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wesolowski</LastName>                    <ForeName>Robert</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Medical Oncology, Department of Internal Medicine, and Division of Surgical Oncology, Department of Surgery, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio; and Division of Medical Oncology, Department of Internal Medicine, Stanford University, Stanford, California.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Haraldsdottir</LastName>                    <ForeName>Sigurdis</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Medical Oncology, Department of Internal Medicine, and Division of Surgical Oncology, Department of Surgery, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio; and Division of Medical Oncology, Department of Internal Medicine, Stanford University, Stanford, California.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Reeser</LastName>                    <ForeName>Julie W</ForeName>                    <Initials>JW</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Medical Oncology, Department of Internal Medicine, and Division of Surgical Oncology, Department of Surgery, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio; and Division of Medical Oncology, Department of Internal Medicine, Stanford University, Stanford, California.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Samorodnitsky</LastName>                    <ForeName>Eric</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Medical Oncology, Department of Internal Medicine, and Division of Surgical Oncology, Department of Surgery, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio; and Division of Medical Oncology, Department of Internal Medicine, Stanford University, Stanford, California.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Smith</LastName>                    <ForeName>Amy</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Medical Oncology, Department of Internal Medicine, and Division of Surgical Oncology, Department of Surgery, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio; and Division of Medical Oncology, Department of Internal Medicine, Stanford University, Stanford, California.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Konda</LastName>                    <ForeName>Bhavana</ForeName>                    <Initials>B</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Medical Oncology, Department of Internal Medicine, and Division of Surgical Oncology, Department of Surgery, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio; and Division of Medical Oncology, Department of Internal Medicine, Stanford University, Stanford, California.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>J Natl Compr Canc Netw</MedlineTA>            <NlmUniqueID>101162515</NlmUniqueID>            <ISSNLinking>1540-1405</ISSNLinking>        </MedlineJournalInfo>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2017</Year>                <Month>12</Month>                <Day>10</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>05</Month>                <Day>03</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30181415</ArticleId>            <ArticleId IdType="pii">16/9/1035</ArticleId>            <ArticleId IdType="doi">10.6004/jnccn.2018.7043</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30181315</PMID>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>05</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1549-490X</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Sep</Month>                        <Day>04</Day>                    </PubDate>                </JournalIssue>                <Title>The oncologist</Title>                <ISOAbbreviation>Oncologist</ISOAbbreviation>            </Journal>            <ArticleTitle>Concordance Study Between IBM Watson for Oncology and Clinical Practice for Patients with Cancer in China.</ArticleTitle>            <ELocationID EIdType="pii" ValidYN="Y">theoncologist.2018-0255</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1634/theoncologist.2018-0255</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">IBM Watson for Oncology (WFO), which can use natural language processing to evaluate data in structured and unstructured formats, has begun to be used in China. It provides physicians with evidence-based treatment options and ranks them in three categories for treatment decision support. This study was designed to examine the concordance between the treatment recommendation proposed by WFO and actual clinical decisions by oncologists in our cancer center, which would reflect the differences of cancer treatment between China and the U.S.</AbstractText>                <AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">Retrospective data from 362 patients with cancer were ingested into WFO from April 2017 to October 2017. WFO recommendations were provided in three categories: recommended, for consideration, and not recommended. Concordance was analyzed by comparing the treatment decisions proposed by WFO with those of the multidisciplinary tumor board. Concordance was achieved when the oncologists' treatment decisions were in the recommended or for consideration categories in WFO.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Ovarian cancer showed the highest concordance, which was 96%. Lung cancer and breast cancer obtained a concordance of slightly above 80%. The concordance of rectal cancer was 74%, whereas colon cancer and cervical cancer showed the same concordance of 64%. In particular, the concordance of gastric cancer was very low, only 12%, and 88% of cases were under physicians choice.</AbstractText>                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Different cancer types showed different concordances, and only gastric cancers were significantly less likely to be concordant. Incidence and pharmaceuticals may be the major cause of discordance. To be comprehensively and rapidly applied in China, WFO needs to accelerate localization. ClinicalTrials.gov Identifier: NCT03400514.</AbstractText>                <AbstractText Label="IMPLICATIONS FOR PRACTICE" NlmCategory="CONCLUSIONS">IBM Watson for Oncology (WFO) has begun to be used in China. In this study, concordance was examined between the treatment recommendation proposed by WFO and clinical decisions for 362 patients in our cancer center, which could reflect the differences of cancer treatment between China and the U.S. Different cancer types showed different concordances, and only gastric cancers were significantly less likely to be concordant. Incidence and pharmaceuticals may be the major causes of discordance. To be comprehensively and rapidly applied in China, WFO needs to accelerate localization. This study may have a significant effect on application of artificial intelligence systems in China.</AbstractText>                <CopyrightInformation>© AlphaMed Press 2018.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Zhou</LastName>                    <ForeName>Na</ForeName>                    <Initials>N</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, the Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhang</LastName>                    <ForeName>Chuan-Tao</ForeName>                    <Initials>CT</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, the Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lv</LastName>                    <ForeName>Hong-Ying</ForeName>                    <Initials>HY</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, the Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hao</LastName>                    <ForeName>Chen-Xing</ForeName>                    <Initials>CX</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, the Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Li</LastName>                    <ForeName>Tian-Jun</ForeName>                    <Initials>TJ</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, the Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhu</LastName>                    <ForeName>Jing-Juan</ForeName>                    <Initials>JJ</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, the Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhu</LastName>                    <ForeName>Hua</ForeName>                    <Initials>H</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, the Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Jiang</LastName>                    <ForeName>Man</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, the Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Liu</LastName>                    <ForeName>Ke-Wei</ForeName>                    <Initials>KW</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, the Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hou</LastName>                    <ForeName>He-Lei</ForeName>                    <Initials>HL</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, the Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Liu</LastName>                    <ForeName>Dong</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, the Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Li</LastName>                    <ForeName>Ai-Qin</ForeName>                    <Initials>AQ</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Out-patient, the Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhang</LastName>                    <ForeName>Guo-Qing</ForeName>                    <Initials>GQ</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Thoracic Surgery, the Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Tian</LastName>                    <ForeName>Zi-Bin</ForeName>                    <Initials>ZB</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Gastroenterology, the Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhang</LastName>                    <ForeName>Xiao-Chun</ForeName>                    <Initials>XC</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, the Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, China zhangxiaochun9670@126.com.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <DataBankList CompleteYN="Y">                <DataBank>                    <DataBankName>ClinicalTrials.gov</DataBankName>                    <AccessionNumberList>                        <AccessionNumber>NCT03400514</AccessionNumber>                    </AccessionNumberList>                </DataBank>            </DataBankList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>04</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Oncologist</MedlineTA>            <NlmUniqueID>9607837</NlmUniqueID>            <ISSNLinking>1083-7159</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Artificial Intelligence</Keyword>            <Keyword MajorTopicYN="N">China</Keyword>            <Keyword MajorTopicYN="N">Concordance</Keyword>            <Keyword MajorTopicYN="N">Watson for Oncology</Keyword>        </KeywordList>        <CoiStatement>Disclosures of potential conflicts of interest may be found at the end of this article.</CoiStatement>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>04</Month>                <Day>28</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>07</Month>                <Day>06</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30181315</ArticleId>            <ArticleId IdType="pii">theoncologist.2018-0255</ArticleId>            <ArticleId IdType="doi">10.1634/theoncologist.2018-0255</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>